Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Kongyuan Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5288-642X; OpenAlex author ID A5031522754, A5108315122, A5152407340. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2021: 2 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: 3 papers · 2026: 3 papers

Papers 10

  1. Patient survival outcomes in brain metastases of pancreatic ductal adenocarcinoma: A comprehensive analysis. Co-author DOI 10.1016/j.ctarc.2026.101266↗
  2. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  3. [Acute pancreatitis in pancreatic cancer: impact on prognosis:a retrospective single-center cohort study]. Co-author DOI 10.3760/cma.j.cn112139-20260109-00017↗
  4. Characterization and treatment of brain metastases from pancreatic cancer: a systematic review. Last author DOI 10.1007/s12672-025-02623-y↗
  5. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18212-w↗
  6. Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma:… Co-author DOI 10.3389/fimmu.2025.1654425↗
  7. Minimally invasive versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: Individual patient data meta-analysis of randomized trials. First author DOI 10.1016/j.ejso.2023.03.227↗
  8. Corrigendum: Clinical impact of molecular subtyping of pancreatic cancer. Co-author DOI 10.3389/fcell.2023.1179559↗
  9. Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.743908↗
  10. Surgical Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13081971↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Benedetto Ielpo · 3 shared papers, 2023–2026 · strength 0.57
  2. Marc G. Besselink · 3 shared papers, 2023–2026 · strength 0.57
  3. Thilo Hackert · 3 shared papers, 2021–2023 · strength 0.54
  4. Allegra Ripolli · 2 shared papers, 2025–2026 · strength 0.41
  5. Emanuele F. Kauffmann · 2 shared papers, 2025–2026 · strength 0.41
  6. Riccardo Casadei · 2 shared papers, 2025–2026 · strength 0.41
  7. Sergio Alfieri · 2 shared papers, 2025–2026 · strength 0.41
  8. V. Egorov · 2 shared papers, 2025–2026 · strength 0.41
  9. Gregory G. Tsiotos · 2 shared papers, 2025–2026 · strength 0.41
  10. Alessandro Zerbi · 2 shared papers, 2025–2026 · strength 0.41
  11. Yuichi Nagakawa · 2 shared papers, 2025–2026 · strength 0.41
  12. Niccolò Napoli · 2 shared papers, 2025–2026 · strength 0.41
  13. Elena B. Rangelova · 2 shared papers, 2025–2026 · strength 0.41
  14. Emilio Vicente · 2 shared papers, 2025–2026 · strength 0.41
  15. Ugo Boggi · 2 shared papers, 2025–2026 · strength 0.41
  16. Giuseppe Fusai · 2 shared papers, 2025–2026 · strength 0.41
  17. Roberto Coppola · 2 shared papers, 2025–2026 · strength 0.41
  18. Yuanchi Ma · 1 shared paper, 2026 · strength 0.33
  19. Hairong He · 1 shared paper, 2026 · strength 0.33
  20. Liang Han · 1 shared paper, 2026 · strength 0.33
  21. H R He · 1 shared paper, 2026 · strength 0.32
  22. B Y Li · 1 shared paper, 2026 · strength 0.32
  23. Liang Han · 1 shared paper, 2025 · strength 0.27
  24. Hairong He · 1 shared paper, 2025 · strength 0.27
  25. Weikun Qian · 1 shared paper, 2025 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.